These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34237488)

  • 1. Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis.
    Boman C; Zerdes I; Mårtensson K; Bergh J; Foukakis T; Valachis A; Matikas A
    Cancer Treat Rev; 2021 Sep; 99():102257. PubMed ID: 34237488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers.
    Rozenblit M; Huang R; Danziger N; Hegde P; Alexander B; Ramkissoon S; Blenman K; Ross JS; Rimm DL; Pusztai L
    J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33239417
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of discordance in programmed death-ligand 1 (PD-L1) expression between primary tumors and paired distant metastases in advanced cancers: a systematic review and meta-analysis.
    Lee CC; Soon YY; Lum JHY; Tan CL; Tey JCS
    Acta Oncol; 2020 Jun; 59(6):696-704. PubMed ID: 32193962
    [No Abstract]   [Full Text] [Related]  

  • 4. Primary tumor resection for initially staged IV breast cancer: An emphasis on programmed death-ligand 1 expression, promoter methylation status, and survival.
    Erol T; İmamoğlu NE; Aydin B; Taşkiran ZE; Esendağli G; Kösemehmetoğlu K; Baykal A
    Medicine (Baltimore); 2019 Aug; 98(33):e16773. PubMed ID: 31415379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases.
    Manson QF; Schrijver WAME; Ter Hoeve ND; Moelans CB; van Diest PJ
    Clin Exp Metastasis; 2019 Feb; 36(1):29-37. PubMed ID: 30547271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
    Tawfik O; Kimler BF; Karnik T; Shehata P
    Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Implications of PD-L1 Expression in Breast Cancer: Systematic Review and Meta-analysis of Immunohistochemistry and Pooled Analysis of Transcriptomic Data.
    Matikas A; Zerdes I; Lövrot J; Richard F; Sotiriou C; Bergh J; Valachis A; Foukakis T
    Clin Cancer Res; 2019 Sep; 25(18):5717-5726. PubMed ID: 31227501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    Kim HM; Lee J; Koo JS
    BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
    Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
    Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Expression and Intratumoral Heterogeneity Across Breast Cancer Subtypes and Stages: An Assessment of 245 Primary and 40 Metastatic Tumors.
    Dill EA; Gru AA; Atkins KA; Friedman LA; Moore ME; Bullock TN; Cross JV; Dillon PM; Mills AM
    Am J Surg Pathol; 2017 Mar; 41(3):334-342. PubMed ID: 28195880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discordance of immunotherapy response predictive biomarkers between primary lesions and paired metastases in tumours: A systematic review and meta-analysis.
    Zou Y; Hu X; Zheng S; Yang A; Li X; Tang H; Kong Y; Xie X
    EBioMedicine; 2021 Jan; 63():103137. PubMed ID: 33310681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain metastasis PD-L1 and CD8 expression is dependent on primary tumor type and its PD-L1 and CD8 status.
    Camy F; Karpathiou G; Dumollard JM; Magne N; Perrot JL; Vassal F; Picot T; Mobarki M; Forest F; Casteillo F; Hathroubi S; Froudarakis M; Peoc'h M
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis.
    Tonse R; Rubens M; Appel H; Tom MC; Hall MD; Odia Y; McDermott MW; Ahluwalia MS; Mehta MP; Kotecha R
    Neurooncol Adv; 2021; 3(1):vdab166. PubMed ID: 34988451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
    Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
    Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Heterogeneity in PD-L1 expression on infiltrating immune cells between the primary and metastatic breast cancers].
    Wang XR; Zhang NN; Lyu F; Wang HL; Liu YP
    Zhonghua Bing Li Xue Za Zhi; 2020 May; 49(5):430-434. PubMed ID: 32392925
    [No Abstract]   [Full Text] [Related]  

  • 17. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
    Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
    Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors.
    Guo H; Ding Q; Gong Y; Gilcrease MZ; Zhao M; Zhao J; Sui D; Wu Y; Chen H; Liu H; Zhang J; Resetkova E; Moulder SL; Wang WL; Huo L
    Breast Cancer Res; 2020 Jun; 22(1):69. PubMed ID: 32576238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1.
    Dill EA; Dillon PM; Bullock TN; Mills AM
    Mod Pathol; 2018 Oct; 31(10):1513-1522. PubMed ID: 29802358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor mutation burden, immune checkpoint crosstalk and radiosensitivity in single-cell RNA sequencing data of breast cancer.
    Jang BS; Han W; Kim IA
    Radiother Oncol; 2020 Jan; 142():202-209. PubMed ID: 31767471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.